New review article on mHSPC and mCRPC

Below you will find a link to a valuable new review article on ongoing changes in the opportunities for evaluation and management of men with both hormone-sensitive and castration-resistant, metastatic prostate cancer (mHSPC and mCRPC). … READ MORE …

Brachy boost therapy should be reserved for unfavorable risk patients

The ASCENDE-RT trial showed that oncological outcomes were improved among both intermediate-risk and high-risk men who were treated with external beam radiation (EBRT) and a brachytherapy boost (LDR-BT) to the prostate and adjuvant androgen deprivation therapy (ADT) (see this link). … READ MORE …

Cancer tissue subtypes and prostate cancer prognosis

A newly published article in JAMA Oncology is asking whether there is a completely different way to look at how to classify prostate cancer tissue types and correlate such classification to responses to treatment using certainly classes of drugs. … READ MORE …

Dose-escalated radiation therapy doesn’t impact survival within 10 years

Zaorsky et al. conducted a meta-analysis of 12 randomized clinical trials covering data on 6,884 patients treated with external beam radiation at various dose levels. … READ MORE …

A future with too many tests and no comparative data about value?

The role of personalized genetic and genomic testing and the value of such testing to test to accurately and reliably predict things like the appropriateness of active surveillance as a management strategy or the risk for recurrence after first-line surgery is now evolving at almost bewildering speed. … READ MORE …

The future of cancer classification — a molecular realignment

Traditionally cancers have been classified according to their organ system of origin: prostate cancer, breast cancer, color-rectal cancer, etc. For several years now, it has been evident that this historic classification system needed a major overhaul … and that overhaul is now coming closer. … READ MORE …

Your blood type may affect your risk for prostate cancer mortality

Perhaps the most fascinating paper to be presented this year at the Genitourinary Cancers Symposium has to do with blood typing and risk for lethal prostate cancer. … READ MORE …